Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Investigation of Faldaprevir Effect on Steady State Pharmacokinetics of Raltegravir in Healthy Male and Female Volunteers (an Open-label Trial With Two Periods in a Fixed Sequence)

Trial Profile

Investigation of Faldaprevir Effect on Steady State Pharmacokinetics of Raltegravir in Healthy Male and Female Volunteers (an Open-label Trial With Two Periods in a Fixed Sequence)

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2015

At a glance

  • Drugs Faldaprevir (Primary) ; Raltegravir (Primary)
  • Indications Hepatitis C; HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 06 Mar 2014 Results presented at the 21st Conference on Retroviruses and Opportunistic Infections.
    • 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top